Breakthrough Solutions for Effective Therapies

Pictogramme tumeur


Anti-Cancer Solutions Targeting metastasis, failure and drug resistance

Pictogramme tumeur


Preventing cancers by Treating Obesity

Pictogramme tumeur

Viral Infection

Example : targeting adipose tissue HIV reservoir and  Covid19

About us


THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patents in January 2023.

THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.

Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex 
Zakia Belaid-Choucair(*) et  al .Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): 
AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3293. doi:10.1158/1538-7445.AM2014-3293. * Dr. ZAKIA BELAID-SANDAL (PhD)  ( Widow Choucair)

Theranovir rewards


THERANOVIR is a winner of :

  • Lab-SHAKER 2017 (Genopole),
  • Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
  • HEC-Challenge+ 2019 (HEC Paris),
  • Ilab 2020 (Ministry of education and research),
  • Innov’up PIA 2021 (Ile-de-France region) competitions.
  • NETVA Start in America 2024



Operational team


Co-founder-President / CEO/CSO

17 years of experience in leading and participating in oncology programs in France and abroad

3 co-invented patents

(MD PhD)

Associate/ Scientific/Clinical Advisor

KOL for immuno-onco therapies, experience in leading European cancer institutions

Former General Manager of  French Institute of Cancer Gustave ROUSSY

Elie MATTA (PhD)

Assistant Scientific Investigator

PhD in Oncology and Cancer Biology

Co-author of 3 publications in DNA Repair

Advisory Board


Expert in  Clinical Development

Oncology and Infectious diseases area
Former Medical Director at Bayer-Healthcare


Expert  in molecular oncology and

DNA Repair and Damage
CEO of  Cell Environment

(MD PhD)

President of Cancéropôle Ile de France

Deputy Director of CARPEM and KOL for anti-cancer immuno-oncology


Christophe de ROMEUF


Expert  in monoclonal antibody preclinical studies, data room and team management.

CRBioconsult, France

Alexandre FONTAYNE

Expertise in Drug Design and preclinical R&D

Former President of Biothelis SAS, President and expert of BE4S consulting

They support us


Laureat NETVA 2024


Head Office

Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes

Laboratory R&D

Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif




+ 33 1 42 11 60 43

This site is under construction. 

Come back in a few weeks to discover our expertise in details.